ANTH Stock UPDATES Anthera Pharmaceuticals (ANTH) 1.89 10/22/2014

New Post Public Reply Private Reply Replies (0) Message Board

Oct 22, 2014 at 1:31 PM

Anthera Pharmaceuticals (ANTH) 1.89 $ANTH

Anthera Pharmaceuticals Announces Update on Strategic Partnership Discussions for Blisibimod
PR Newswire - Wed Oct 01, 3:00PM CDT
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) today confirmed it is engaged in potential partnership negotiations for blisibimod for both lupus and IgA nephropathy in territories outside the United States.
ANTH: 1.89 (unch)

4 Stocks Under $10 to Trade for Breakouts
at The Street - Wed Oct 01, 6:00AM CDT
These under-$10 stocks are within range of triggering breakout trades.
ROIAK: 2.63 (-0.12), ANTH: 1.89 (unch), TRXC: 4.12 (unch), SYMX: 0.97 (+0.03)

Qiagen's Molecular Diagnostics, Global Market Show Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 1:50PM CDT
On Sep 25, we issued an updated research report on Qiagen N.V. (QGEN).
HSKA: 12.22 (+0.06), GILD: 105.55 (-1.12), ANTH: 1.89 (unch), QGEN: 22.50 (-0.08)

Genomic Health Upbeat on Strong International Performance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 2:00PM CDT
Genomic Health (GHDX) is focused on delivering revenue growth through constant investment for higher adoption of its tests across three major cancers
CBM: 17.78 (-0.10), GILD: 105.55 (-1.12), ANTH: 1.89 (unch), GHDX: 33.06 (-0.70)

Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
ARC: 9.69 (-0.04), BIDU: 220.67 (-1.68), ANTH: 1.89 (unch), AMGN: 142.37 (-1.72), ALSN: 29.20 (+0.04)

Market Maker Surveillance Report. PDLI, AT, ISNS, QLTI, SINO, ANTH, Losing Stocks With Lowest Price Friction For Wednesday, September 17th 2014
M2 - Thu Sep 18, 3:31AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4737 companies with "abnormal" market making, 2409 companies with positive Friction Factors and 2599 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Wednesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. PDL Biopharma Inc (NASDAQ

DLI), ATLANTIC POWER CORP (NYSE:AT), Image Sensing Systems Inc (NASDAQ:ISNS), QLT INC (NASDAQ:QLTI), Sino-Global Shipping America Ltd (NASDAQ:SINO), Anthera Pharmaceuticals Inc (NASDAQ:ANTH). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
AT: 2.26 (-0.03), QLTI: 4.00 (+0.01), ANTH: 1.89 (unch), ISNS: 3.08 (+0.53), SINO: 1.85 (-0.19), PDLI: 8.22 (+0.05)

Anthera (ANTH) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 9:41AM CDT
Anthera (ANTH) Enters Oversold Territory
ANTH: 1.89 (unch)

Anthera Pharmaceuticals (ANTH) Sees Hammer Chart Pattern: Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 8:31AM CDT
Anthera Pharmaceuticals (ANTH) Sees Hammer Chart Pattern: Time to Buy?
ANTH: 1.89 (unch)

Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update
PR Newswire - Mon Jul 28, 4:40PM CDT
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and operational update for the second quarter ended June 30, 2014.
ANTH: 1.89 (unch)

The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune
PR Newswire - Mon Jul 21, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH-Free Report), Amgen, Inc. (Nasdaq:AMGN-Free Report), Eli Lilly and Company (NYSE:LLY-Free Report), Actelion Ltd. (OTC:ALIOF-Free Report) and InterMune, Inc. (Nasdaq:ITMN-Free Report).
ANTH: 1.89 (unch), AMGN: 142.37 (-1.72), LLY: 64.83 (+0.15)

Anthera Acquires Sollpura from Eli Lilly - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 18, 4:20PM CDT
Anthera Pharmaceuticals (ANTH) acquired mid-stage development candidate, Sollpura, from Eli Lilly and Company (LLY).
ANTH: 1.89 (unch), AMGN: 142.37 (-1.72), LLY: 64.83 (+0.15)

Exelixis (EXEL) Soars: Stock Adds 23% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 8:04AM CDT
Exelixis, Inc. (EXEL) was a big mover last session, as the company saw its shares rise 23% on the day.
BIIB: 303.97 (-22.80), ANTH: 1.89 (unch), EXEL: 1.58 (-0.02)

Anthera Pharmaceuticals Announces Acquisition of Sollpura® (liprotamase) for Exocrine Pancreatic Insufficiency From Eli Lilly and Company
PR Newswire - Mon Jul 14, 3:42PM CDT
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) today announced that it has acquired Sollpura (liprotamase), a novel investigational Pancreatic Enzyme Replacement Therapy ("PERT"

from Eli Lilly and Company. Sollpura is a soluble, stable and non-porcine enzyme product intended for the treatment of patients with low digestive enzyme levels, or Exocrine Pancreatic Insufficiency (EPI), due to cystic fibrosis, and potentially other diseases. EPI is characterized by low absorption of fat and other nutrients due to a reduction in digestive enzymes produced by the pancreas.
ANTH: 1.89 (unch), LLY: 64.83 (+0.15)

Biotech Stock Mailbag: MannKind, Bluebird, Northwest Bio, More '14 Tradable Biotech Events
at The Street - Mon Jul 14, 8:30AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
ACRX: 6.64 (-0.21), INO: 11.01 (-0.54), NWBO: 4.75 (-0.34), OPK: 8.23 (-0.16), CPRX: 2.47 (-0.08), ANTH: 1.89 (unch), NBS: 5.14 (-0.26), PPHM: 1.45 (-0.03), MNKD: 5.40 (-0.13), DSCO: 1.90 (-0.04)

Anthera Pharmaceuticals Appoints Brian R. Mueller to Board of Directors
PR Newswire - Mon Jun 23, 4:00PM CDT
Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, today announced the appointment of Brian R. Mueller to its Board of Directors and as Chairman of the Audit Committee of the Board of Directors. Mr. Brian R. Mueller currently serves as Group Vice President, Corporate Controller and Chief Accounting Officer of BioMarin Pharmaceutical Inc., a publicly-traded biopharmaceutical company and has been with BioMarin since 2002. Prior to BioMarin, Mr. Mueller spent a combination of seven years in public accounting in Arthur Andersen, LLP and KPMG, LLP. Mr. Mueller holds a B.S. in accounting from Northern Illinois University.
BMRN: 75.00 (+0.29), ANTH: 1.89 (unch)

Anthera Pharmaceuticals names Dr Philip Sager to board
M2 - Mon Jun 16, 3:49AM CDT
Biopharmaceutical company Anthera Pharmaceuticals (NasdaqGM:ANTH) disclosed on Friday the addition of Philip Sager MD FACC FAHA FHRS to its board of directors.
ANTH: 1.89 (unch)

Anthera Pharmaceuticals Appoints Dr. Philip Sager to Board of Directors
PR Newswire - Fri Jun 13, 2:30PM CDT
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, today announced the appointment of Dr. Philip Sager, MD, FACC, FAHA, FHRS, to its Board of Directors.
GILD: 105.55 (-1.12), ANTH: 1.89 (unch)

Anthera Pharmaceuticals Announces Personnel Changes
PR Newswire - Mon Mar 31, 3:30PM CDT
Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, today announced the appointment of Steven Engle to and the departure of Dr. James Healy, MD, PhD from its Board of Directors.
ANTH: 1.89 (unch)

Anthera Pharmaceuticals Reports 2013 Fourth Quarter And Fiscal Year Financial Results and Operational Update
PR Newswire - Wed Mar 12, 5:01PM CDT
Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and operational update for the fourth quarter and year ended December 31, 2013.
ANTH: 1.89 (unch)

Global Systemic Lupus Erythematosus and Lupus Nephritis Drug Forecast and Market Analysis to 2022
M2 - Thu Feb 27, 4:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/3dtg7v/pharmapoint) has announced the addition of the "PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022" report to their offering. Sales for SLE and LN by Region, 2012-2022 2012 Systemic Lupus Erythematosus (SLE) drug sales to be over $473.6m across the seven major markets covered in this report: US, France, Germany, Italy, Spain, UK and Japan. By the end of the forecast period in 2022, sales will grow to over $1.1 billion with a CAGR of 9.36%. Focusing on Lupus Nephritis (LN), The authors estimates 2012 drug sales to be over $216.6m across the seven major markets covered in this report. By the end of the forecast period in 2022, sales will grow to over $505.9m with a CAGR of 8.86%. The growth in the SLE and LN therapeutics will be driven by: - Increasing uptake of biologics, including GlaxoSmithKline's Benlysta (belimumab), the only approved biologic for SLE, and off-label use of Roche's Rituxan - The launch of Benlysta in Japan in 2016 - The launch of new biologic drugs during the second half of the forecast period - The increasing number of prevalent cases of SLE and LN The uptake of new biologic drugs that will enter the SLE and LN markets will be initially low. Biologic drugs will primarily target lupus patients with high disease activity (approximately 10%-15% of all SLE patients) and therefore, currently marketed biologic dugs and new entrants will compete for a small segment of the total SLE patient population. This view is based on the available clinical trial data to date for Benlysta, the clinical trial design for current pipeline products and The authors's primary research (conducted in July-August 2013). Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook Companies Mentioned - GlaxoSmithKline - Roche - UCB - Eli Lilly and Company - Bristol-Myers Squibb - Anthera Pharmaceuticals - ImmuPharma - Merck Serono For more information visit http://www.researchandmarkets.com/research/3d...harmapoint
ANTH: 1.89 (unch), MRK: 55.50 (+0.37), LLY: 64.83 (+0.15), GSK: 44.61 (+0.98), BMY: 52.02 (+0.07)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kyndryl's Sovereignty Strategy Tackles Digital Resilience

Driving Resilience Amidst Sovereignty Moves Hot off the press, Kyndryl is rolling out a beefed-up strategy to fortify operational resilience in the face of shifting digital sovereignty challenges. I’d say these guys got their fingers firmly on the geopolitical pulse, and they’re not messing around. “Maintaining critical IT operations is fundamental to business...

Four Seasons' New Palau Hub: A Game-Changer for Luxury

Four Seasons Stirs Up the Luxury Travel Scene Alright, every once in a blue moon, you get this kind of roll-out from a hospitality giant that even gets a stone-cold trader to raise an eyebrow. Four Seasons isn't just any hotel chain; it's a heavyweight in the luxury sector. They're pulling the wraps off their new spot in Palau, and it's about as plush as it gets. They're...

Clean Tech's Dual Role: Energy Resilience and Dependency

Technology's Double-Edged Sword in Energy You ever chat with someone about moving your whole life onto solar? Seems greener and cheaper, right? But dive into the numbers, and you'll see it comes with its own set of strings attached. According to a fresh-off-the-press report from S&P Global, clean tech is both a saving grace and a looming liability economically and...

Triller Faces Legal Storm: Investor Action Deadline Looms

Triller Group Inc. Lands in Hot Water Ah, the stock market—it’s like playing poker in a storm. And here we stand, facing the mess Triller Group Inc. has gotten into. Known on the market as NASDAQ:ILLRW, Triller has caught itself in a legal tug-of-war over some nasty allegations. If you held shares during the period between October 16, 2024, and December 29, 2025, you...

Keurig Dr Pepper's Bold $2B Offering: Strategic Shift

Strategic Moves Behind KDP's $2 Billion Offering Walking through all this, Keurig Dr Pepper (NASDAQ:KDP) has set the stage for something big. Yeah, I'm talking about a hefty $2 billion underwritten public offering. It's one of those moves where you're either shaking your head in confusion or nodding in cautious approval. With the coffee behemoth taking this step, let's...

Silicosis Crisis: Legal and Health Ramifications Loom

The Hidden Dangers of Artificial Stone Here's the grim truth. Artificial stone countertops, loved by many for their aesthetics in kitchens and bathrooms, have a dark side that’s becoming increasingly hard to ignore. Loaded with more than 90% respirable crystalline silica, these materials spew out toxic dust when cut or polished. Once that dust gets airborne, workers...

Tigo Energy Lawsuit: Shareholders' Fight for Justice

Energy Optimism or Illusion? Is it a bright future when projections fizzle out faster than a lukewarm coffee on a cold morning? If you snapped up shares of Tigo Energy (NASDAQ: TYGO) thinking you were hitching your wagon to a rising solar star, the latest class action might just feel like a gut punch. Tangled Partnership Promises Let's cut to the core of the issue. Tigo...

Flyers Fundraiser Supports Mental Health Advocacy in NJ and PA

Blockbusters on Ice, Support Beyond the Rink Here's a twist for hockey fans out there: snagging tickets to catch the Philadelphia Flyers might pack more punch off the ice than on it. Why? Because, for every ticket you grab through Digital Elements Group's special link, $5 is pumped straight into the veins of mental health advocacy in New Jersey and Pennsylvania. Pretty...

Universal Music CFO to Speak at Major Tech Conference

UMG Steps into the Spotlight at Morgan Stanley Event Music, money, and technology—it's a compelling trio. Universal Music Group (EURONEXT: UMG) is sending its heavyweights, Matt Ellis and Michael Nash, to the Morgan Stanley European Technology, Media & Telecom Conference on November 18, 2026. This isn't just any run-of-the-mill industry hobnob. We're talking about the...

Untapped $41B VA Loan Potential: Opportunities Missed

VA Loans: Unused Potential Sits at $41 Billion Are you telling me we're leaving $41 billion just sitting on the table in the form of untapped VA loans? That's the figure staring us in the face according to Veterans United's latest analysis. It's not just about numbers; it's a head-scratcher given the growing VA loan market share, which hit 10% last year. Where's the...